Omeros closed at $17.17 on Nov 5, down 5.56%, 18.4% below its 52-week closing high. Volume of 537.6K shares was 0.46× its 20-day average (below normal).
Split-adjusted performance: -8.4% over one month, +17.3% over six months, +155.1% over one year.
In the quarter ended Jun 30, 2026, revenue was $28.53M, with a net margin of 46.4%.
Short interest was 11.4M shares at the Oct 15 settlement (17.8% of float, 12.2 days to cover).
No reported quarters with price history yet.
Percentile among 418 companies (100 = best)
Industry medians: 6-month return −27.4%, revenue growth +5.9%, net margin −37.5%, P/E 15.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| OMEROmeros | $17.17 | −5.56% | +17.3% | — | 46.4% | 10.0 | $1.24B | |
| LBRXLB Pharmaceuticals | $38.74 | −5.18% | +21.1% | — | — | — | $1.25B | Compare |
| NKTRNektar Therapeutics | $36.01 | −6.42% | −56.8% | −9.3% | −401.0% | — | $1.23B | Compare |
| OPKOpko Health | $1.69 | −4.47% | +51.0% | +4.3% | −5.1% | — | $1.26B | Compare |
| MNKDMannkind | $3.75 | −4.61% | +5.6% | +42.9% | −17.4% | — | $1.21B | Compare |
| URGNUroGen Pharma | $26.21 | −8.80% | −1.4% | +199.2% | −19.8% | — | $1.29B | Compare |
| AMPHAmphastar Pharmaceuticals | $27.86 | −0.59% | +15.9% | +5.4% | 16.5% | 15.1 | $1.18B | Compare |
| AVLNAvalyn Pharma | $26.55 | −3.35% | — | — | — | — | $1.18B | Compare |
| DMRADamora Therapeutics | $21.32 | −7.08% | — | — | — | — | $1.32B | Compare |
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
